HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.

AuthorsBetty Lamothe, Fabiola Cervantes-Gomez, Mariela Sivina, William G Wierda, Michael J Keating, Varsha Gandhi
JournalBlood (Blood) Vol. 125 Issue 2 Pg. 407-10 (Jan 08 2015) ISSN: 1528-0020 [Electronic] United States
PMID25573971 (Publication Type: Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Oligopeptides
  • Piperidines
  • Proteasome Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • carfilzomib
  • Adenine
Topics
  • Adenine (analogs & derivatives)
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Apoptosis (drug effects)
  • Blotting, Western
  • Female
  • Humans
  • In Vitro Techniques
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Male
  • Middle Aged
  • Oligopeptides (administration & dosage)
  • Piperidines
  • Proteasome Inhibitors (administration & dosage)
  • Pyrazoles (administration & dosage)
  • Pyrimidines (administration & dosage)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: